Environmental Sustainability Success Stories From the Pharmaceutical and Medtech Industries in Europe: A Targeted Literature Review

Author(s)

Hamilton L1, Goldman E2, Dehipawala S2, O'Hara M2
1Trinity Life Sciences, Washington DC, DC, USA, 2Trinity Life Sciences, Waltham, MA, USA

OBJECTIVES: The healthcare industry generates ~4-5% of global greenhouse gas emissions. As part of their commitment to improving human health, pharmaceutical and MedTech companies are beginning to develop products and processes that prioritize sustainability. This shift has yielded early successes but is still in its initial phases. This targeted literature review aimed to identify recent examples of successful implementation of sustainability initiatives in these industries and opportunities for continued progress.

METHODS: Literature published between June 2020 and 2023 were identified from PubMed, Embase, and Google, focusing on pharmaceutical and MedTech companies’ environmental impact and sustainability efforts, as well as the business implications of these initiatives. Peer-reviewed literature and company-generated reports were captured.

RESULTS: Data were extracted from 27 sources, including 15 environmental impact reports from pharmaceutical and MedTech companies, 4 manuscripts, and 8 government/organization reports. Companies looked beyond carbon emissions to examine water use, raw materials sourcing, and waste generation. High-impact success stories were identified, most notably from European companies focusing on sustainability across the product lifecycle. In the early phases of product development, AstraZeneca partners with My Green Lab, a nonprofit providing accreditations and guidance on in-lab behavioral changes related to energy consumption. This has yielded over 1 million kWh/year in energy savings. Philips’s EcoDesign initiative, focusing on energy efficiency, raw materials use, and recyclability, yielded €1.63 billion in savings in 2022, and these standards will be used in all new product development by 2025.

CONCLUSIONS: These initial success stories may signal a shift to industry-wide recognition of the criticality of sustainability and its associated business benefits. Although not all companies are prioritizing sustainability, early actors are advancing a more holistic and financially sound long-term approach to improving human health. Future research on sustainability initiatives should seek to further understand return on investment decisions, supply chain implications, and analyzing waste impact.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

OP16

Topic

Organizational Practices

Topic Subcategory

Best Research Practices, Ethical, Industry

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×